Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial
British Journal of Dermatology, 05/01/2012
Clinical Article
Bissonnette R et al. – WBI–1001 is an efficacious novel topical anti–inflammatory molecule for the treatment of atopic dermatitis (AD).



